Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment
Mariëtte I.E. van Poelgeest(Leiden University), Sjoerd H. van der Burg(Leiden University Medical Center), Jan W. Drijfhout(Leiden University), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Marc van Beurden(Oncode Institute), Claudia Heijmans‐Antonissen, Manon van Seters(Erasmus MC), Gemma G. Kenter(European Organisation for Research and Treatment of Cancer), Kitty M.C. Kwappenberg(Leiden University Medical Center), Theo J.M. Helmerhorst(Unknown), Rienk Offringa(German Cancer Research Center)
Cited by 92
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840